Commission approves €400 million German state aid to enhance insulin supply resilience
Approved state aid aims to strengthen insulin supply resilience in Germany, supporting future availability of this medicine.
Source →The trace
How it reaches your house.
Starting from Recombinant Insulin API (Bulk Drug Substance), we walked the supply graph hop by hop to the goods you buy and the companies you own. Each step is the engine’s reasoning, scored for confidence and cited where a source backs it.
First impact
Recombinant Insulin API (Bulk Drug Substance) →supply upRecombinant insulin API is a critical direct input to insulin production, so improved API resilience should increase finished-insulin availability.
97% confidenceRecombinant Insulin API (Bulk Drug Substance) →supply upNovo NordiskNVO
Novo Nordisk has the largest listed dependence on this input, so better API supply should improve its insulin production continuity.
89% confidenceRecombinant Insulin API (Bulk Drug Substance) →supply upHop 2
Intas Pharmaceuticals / Accord Healthcare →Stands to benefitRecombinant Insulin API (Bulk Drug Substance)
German state aid aimed at improving insulin supply resilience should support Intas/Accord's insulin production and modestly benefit its recombinant insulin API supplier, but the dependency is only 5% so the transmission is limited.
46% confidence